Sugi Predict

Sugi Predict / Compounds / SCHEMBL905633

SCHEMBL905633

SCHEMBL905633

COc1cccc(Nc2nnc(Cc3ccncc3)c3ccccc23)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 18/20 1.00
▸ PDGFRB P09619 11/20 1.00
▸ FLT1 P17948 11/20 1.00
▸ KIT P10721 10/20 1.00
▸ MEN1 O00255 1/20 0.78
▸ KMT2A Q03164 1/20 0.78
▸ SHMT2 P34897 1/20 0.70
▸ CIT O14578 1/20 0.61
▸ EGFR P00533 1/20 0.61
▸ HLA-A P04439 1/20 0.61
▸ CSF1R P07333 1/20 0.61
▸ RET P07949 1/20 0.61
▸ PDGFRA P16234 1/20 0.61
▸ RPS6KB1 P23443 1/20 0.61
▸ FLT4 P35916 1/20 0.61
▸ FRK P42685 1/20 0.61
▸ CDK8 P49336 1/20 0.61
▸ DDR1 Q08345 1/20 0.61
▸ STK3 Q13188 1/20 0.61
▸ PTK6 Q13882 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22680408 0.91 KDR (0.83) KDRPDGFRBFLT1KITMEN1
SCHEMBL905654 0.89 KDR (0.80) KDRPDGFRBFLT1KITMEN1
SCHEMBL905595 0.87 KDR (0.86) KDRPDGFRBFLT1KITSHMT2
SCHEMBL905636 0.86 KDR (0.75) KDRPDGFRBFLT1KITMEN1
SCHEMBL8198715 0.85 KDR (0.73) KDRPDGFRBFLT1KITMEN1
SCHEMBL905704 0.85 KDR (1.00) KDRPDGFRBFLT1KITMEN1
SCHEMBL6611483 0.84 KDR (0.73) KDRPDGFRBFLT1KITMEN1
Hydrochloric Acid SCHEMBL6606364 0.84 KDR (0.72) KDRPDGFRBFLT1KITMEN1
SCHEMBL28021677 0.84 SHMT2 (0.79) KDRPDGFRBFLT1KITMEN1
SCHEMBL905612 0.83 KDR (0.76) KDRPDGFRBFLT1KITMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7268137-B2 Ocular therapy NOVARTIS AG (CH) 2007-09-11 — — US claimed
EP-1105136-B1 METHOD FOR TREATING OCULAR NEOVASCULAR DISEASES NOVARTIS AG (CH) 2007-08-29 — — EP claimed
EP-1641458-A2 PHARMACEUTICAL COMBINATIONS OF PHTHALAZINE VEGF INHIBITORS AND BENZAMIDE HDAC INHIBITORS SCHERING AKTIENGESELLSCHAFT (DE) 2006-04-05 — — EP claimed
US-20050209238-A1 Method for treating ocular neovascular diseases BRAZZELL ROMULUS K 2005-09-22 — — US claimed
US-20050054647-A1 New pharmaceutical combination BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2005-03-10 — — US claimed
EP-0970070-B1 PHTHALAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY NOVARTIS AG (CH) 2004-10-06 — — EP claimed
WO-2004058234-A2 PHARMACEUTICAL COMBINATIONS OF PHTHALAZINE VEGF INHIBITORS AND BENZAMIDE HDAC INHIBITORS SCHERING AKTIENGESELLSCHAFT (DE) 2004-07-15 — — WO claimed
US-20040116434-A1 Ocular therapy NOVARTIS AG (CH) 2004-06-17 — — US claimed
US-20040102444-A1 Method for delivering drugs to the retina CAMPOCHIARO PETER (US) 2004-05-27 — — US claimed
US-20030191129-A1 Phthalazines with angiogenesis inhibiting activity BOLD GUIDO (CH) 2003-10-09 — — US claimed
US-20030171375-A1 Method for treating ocular neovascular diseases NOVARTIS AG (CH) 2003-09-11 — — US claimed
US-20020091261-A1 Phthalazines with angiogenesis inhibiting activity BOLD GUIDO (CH) 2002-07-11 — — US claimed
US-6271233-B1 ADMINISTERING PHTHALAZINE DERVIVATIVES FOR TREATMENT AND PREVENTION OF RETINAL AND CHOROIDAL NEOVASCULARIZATION, EXUDATIVE AGE RELATED MACULAR DEGENERATION, PROLIFERATIVE DIABETIC RETINOPATHY, AND/OR ISCHEMIC RETINOPATHIES CIBA VISION CORPORATION 2001-08-07 — — US claimed
US-6258812-B1 ANGIOGENESIS INHIBITORS, ANTITUMOR AGENTS AND CARDIOVASCULAR DISORDERS NOVARTIS AG (CH) 2001-07-10 — — US claimed
EP-1105136-A2 METHOD FOR TREATING OCULAR NEOVASCULAR DISEASES Novartis AG (CH) 2001-06-13 — — EP claimed
WO-2000009098-A2 METHOD FOR TREATING OCULAR NEOVASCULAR DISEASES NOVARTIS AG (CH) 2000-02-24 — — WO claimed
EP-0970070-A1 PHTHALAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY Novartis AG (CH) 2000-01-12 — — EP claimed
WO-1998035958-A1 PHTHALAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY NOVARTIS AG (CH) 1998-08-20 — — WO claimed
US-20250312347-A1 THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS BROWN DENNIS M (US) 2025-10-09 — — US disclosed
WO-1998035958-A1 PHTHALAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY NOVARTIS AG (CH) 1998-08-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250312347-A1 THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS UNG, DPYD, TPMT KDR 3803/4885PDGFRB 4079/4885FLT1 3556/4885
US-20030191129-A1 Phthalazines with angiogenesis inhibiting activity PGF, VEGFA, FLT4 KDR 10/4885PDGFRB 124/4885FLT1 4/4885
US-20030171375-A1 Method for treating ocular neovascular diseases ALDH1A2, VEGFA, FLT4 KDR 4/4885PDGFRB 110/4885FLT1 5/4885
US-20050209238-A1 Method for treating ocular neovascular diseases ALDH1A2, VEGFA, FLT4 KDR 4/4885PDGFRB 110/4885FLT1 5/4885
US-20050054647-A1 New pharmaceutical combination VEGFA, INHA, PGF KDR 229/4885PDGFRB 667/4885FLT1 108/4885
US-20040102444-A1 Method for delivering drugs to the retina ALDH1A2, NR2E3, STRA6 KDR 121/4885PDGFRB 2616/4885FLT1 909/4885
US-20020091261-A1 Phthalazines with angiogenesis inhibiting activity PGF, VEGFA, FLT4 KDR 16/4885PDGFRB 91/4885FLT1 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.